In 13 stage II-III PDAC patients, they identified ~30% of somatic tumor mutations (VAF >1%) in ccfDNA and found evidence of corresponding ctDNA in ~69% of patients that were either the KRAS p.G12D or p.G12C variants (median allele frequency of 0.12%; range: 0.05 to 0.56%) [11]. This evidence concerns the gene KRAS and neoplasm.